NASDAQ:FDMT 4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis $3.76 +0.32 (+9.30%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.72 -0.04 (-1.20%) As of 05/2/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About 4D Molecular Therapeutics Stock (NASDAQ:FDMT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FDMT alerts:Sign Up Key Stats Today's Range$3.46▼$3.8050-Day Range$2.51▼$4.8052-Week Range$2.24▼$28.93Volume501,662 shsAverage Volume833,024 shsMarket Capitalization$174.10 millionP/E RatioN/ADividend YieldN/APrice Target$26.71Consensus RatingModerate Buy Company Overview4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Read More… 4D Molecular Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreFDMT MarketRank™: 4D Molecular Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 471st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus Rating4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst Coverage4D Molecular Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 4D Molecular Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($2.84) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 4D Molecular Therapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 4D Molecular Therapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio4D Molecular Therapeutics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about 4D Molecular Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.13% of the float of 4D Molecular Therapeutics has been sold short.Short Interest Ratio / Days to Cover4D Molecular Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in 4D Molecular Therapeutics has recently increased by 2.77%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield4D Molecular Therapeutics does not currently pay a dividend.Dividend Growth4D Molecular Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.13% of the float of 4D Molecular Therapeutics has been sold short.Short Interest Ratio / Days to Cover4D Molecular Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in 4D Molecular Therapeutics has recently increased by 2.77%, indicating that investor sentiment is decreasing. News and Social Media2.5 / 5News Sentiment0.46 News Sentiment4D Molecular Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for 4D Molecular Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for FDMT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, 4D Molecular Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of 4D Molecular Therapeutics is held by insiders.Percentage Held by Institutions99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 4D Molecular Therapeutics' insider trading history. Receive FDMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FDMT Stock News Headlines4D Molecular Therapeutics Receives FDA RMAT Designation for 4D-150 in Diabetic Macular EdemaMay 3 at 4:43 PM | nasdaq.comFDA awards RMAT status to 4DMT diabetic macular oedema therapyMay 2 at 10:33 AM | finance.yahoo.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 4, 2025 | Golden Portfolio (Ad)4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DMEMay 1 at 8:00 AM | globenewswire.comWeiss Ratings Reiterates "Sell (E+)" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)April 25, 2025 | americanbankingnews.com4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement GrantsApril 12, 2025 | finanznachrichten.de4DMT Announces New Employment Inducement GrantsApril 11, 2025 | globenewswire.com4DMT to Participate in Upcoming Investor ConferencesMarch 27, 2025 | globenewswire.comSee More Headlines FDMT Stock Analysis - Frequently Asked Questions How have FDMT shares performed this year? 4D Molecular Therapeutics' stock was trading at $5.57 at the beginning of the year. Since then, FDMT stock has decreased by 32.5% and is now trading at $3.76. View the best growth stocks for 2025 here. How were 4D Molecular Therapeutics' earnings last quarter? 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) issued its earnings results on Friday, February, 28th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by $0.10. When did 4D Molecular Therapeutics IPO? 4D Molecular Therapeutics (FDMT) raised $101 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair served as the underwriters for the IPO and Chardan was co-manager. Who are 4D Molecular Therapeutics' major shareholders? Top institutional shareholders of 4D Molecular Therapeutics include Peapod Lane Capital LLC (0.42%), Bank of New York Mellon Corp (0.29%), Alps Advisors Inc. (0.07%) and Harbor Capital Advisors Inc. (0.07%). Insiders that own company stock include Global Investors Lp Viking, David Kirn, Scott Bizily and Robert Young Kim. View institutional ownership trends. How do I buy shares of 4D Molecular Therapeutics? Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 4D Molecular Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that 4D Molecular Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings2/28/2025Today5/03/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FDMT CIK1650648 Webwww.4dmoleculartherapeutics.com Phone510-505-2680FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$26.71 High Stock Price Target$40.00 Low Stock Price Target$6.00 Potential Upside/Downside+610.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,840,000.00 Net MarginsN/A Pretax Margin-843,999.81% Return on Equity-28.00% Return on Assets-26.16% Debt Debt-to-Equity RatioN/A Current Ratio17.33 Quick Ratio17.33 Sales & Book Value Annual Sales$37,000.00 Price / Sales4,705.28 Cash FlowN/A Price / Cash FlowN/A Book Value$7.20 per share Price / Book0.52Miscellaneous Outstanding Shares46,302,000Free Float42,853,000Market Cap$174.10 million OptionableOptionable Beta2.89 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:FDMT) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.